Atorvastatin increases intestinal expression of NPC1L1 in hyperlipidemic men
about
Dyslipidaemia of diabetes and the intestineMechanisms and genetic determinants regulating sterol absorption, circulating LDL levels, and sterol elimination: implications for classification and disease riskDe novo lipogenesis and cholesterol synthesis in humans with long-standing type 1 diabetes are comparable to non-diabetic individuals.The chylomicron: relationship to atherosclerosis.Effects of CETP inhibition on triglyceride-rich lipoprotein composition and apoB-48 metabolism.The effects of jiang-zhi-ning and its main components on cholesterol metabolism.Visualization of lipid metabolism in the zebrafish intestine reveals a relationship between NPC1L1-mediated cholesterol uptake and dietary fatty acid.Does rosuvastatin increase serum levels of 25-hydroxy-vitamin D?Glucagon receptor antagonism induces increased cholesterol absorption.Eicosapentaenoic and docosahexaenoic acid supplementation and inflammatory gene expression in the duodenum of obese patients with type 2 diabetes.Cholesterol Contributes to Diabetic Nephropathy through SCAP-SREBP-2 Pathway.Key intestinal genes involved in lipoprotein metabolism are downregulated in dyslipidemic men with insulin resistance.Sustained and selective suppression of intestinal cholesterol synthesis by Ro 48-8071, an inhibitor of 2,3-oxidosqualene:lanosterol cyclase, in the BALB/c mouse.Inhibition of pro-protein convertase subtilisin kexin 9 [corrected] (PCSK-9) as a treatment for hyperlipidaemia.Potential of proprotein convertase subtilisin/kexin type 9 based therapeutics.Plant polyisoprenoids and control of cholesterol level.Effect of statin therapy on plasma proprotein convertase subtilisin kexin 9 (PCSK9) concentrations: a systematic review and meta-analysis of clinical trials.Overactivation of intestinal Sterol Response Element Binding Protein 2 promotes diet-induced non-alcoholic steatohepatitis.Lipid Lowering Therapy and Circulating PCSK9 Concentration.Transporters for the Intestinal Absorption of Cholesterol, Vitamin E, and Vitamin K.Emerging pathways in the regulation of whole body cholesterol flux: therapeutic opportunities to target atherosclerosis?PCSK9 in chronic kidney disease.Rooted in risk: genetic predisposition for low-density lipoprotein cholesterol level associates with diminished low-density lipoprotein cholesterol response to statin treatment.Location, location, location...again.Overactivation of intestinal SREBP2 in mice increases serum cholesterol.Impact of a high-cholesterol diet on expression levels of Niemann-Pick C1-like 1 and intestinal transporters in rats and mice.Lipid Uptake, Metabolism, and Transport in the Larval Zebrafish.Ezetimibe enhances and stabilizes anticoagulant effect of warfarin.Ezetimibe increases intestinal expression of the LDL receptor gene in dyslipidaemic men with insulin resistance.Molecular Pathways Underlying Cholesterol Homeostasis.Erchen Decoction Ameliorates Lipid Metabolism by the Regulation of the Protein CAV-1 and the Receptors VLDLR, LDLR, ABCA1, and SRB1 in a High-Fat Diet Rat Model
P2860
Q26799589-AACF6EA0-E84A-4BC8-9360-FCE3C8860AB3Q27003094-7442696E-3E46-4CB8-BCA9-0D01DAD28DB4Q35077618-EF0DC0CA-18D8-4557-ABEF-FF40F2E7C05DQ35295065-3D24557F-F602-4386-A0CA-5E7FDBF599E1Q35958491-AA8092BE-E4DC-4EF1-984C-21FB50DD0D1BQ35977838-DF79FD9D-4AD3-4627-89A2-DC4F527E7EA4Q36129524-FE0D37FC-F52C-47FC-B6E5-11D8DC77FBA1Q36130004-972CC40C-D576-4744-9C77-B0DDF6AFD3B7Q36197864-6F7BA722-EA9B-4B19-B7ED-693E04A8447BQ37033222-4CFF55F7-727C-4C53-BBB1-11A76E2BCD68Q37392958-34C8FCEF-3007-4DAD-8E2F-239D87819086Q37590276-F0D44EEB-8919-4F5C-8A03-F99B1BF1CA2BQ37707904-0C96BB94-D0BD-43E6-A7D9-0BC96E9801B3Q38001736-46256109-ACF1-44D9-AFFE-ED82B9387ED7Q38078264-0E6FB967-3217-43ED-83C9-B5B9AF80C974Q38133372-98718F3B-2338-489D-AF56-56E972D42398Q38548750-9D844E7B-3225-4ADB-9B35-398740B2B139Q38642491-E71EE18A-612E-4EF9-9A3E-5EF741D9805AQ38643197-4D9691BF-28FD-46FD-A749-DAE162EDD99CQ38768787-4A136808-4EE4-4A99-BD39-A0454E23A282Q38892210-0C8B7705-E59F-4280-9F6C-4078F194DD02Q39022581-D5CAF570-BCAC-4996-8457-00DB25F504DFQ40573729-B903EDAC-DC70-4F4F-B2F9-953F595B30E2Q41830674-9567C661-9770-4633-A7B1-12231BD71AC0Q41880154-D9AC956A-4E3E-4C24-A95E-E0E47506A819Q46767535-DA670364-6A49-49AE-A59A-D853B4BC6AFBQ47165156-2D947649-EA2D-4367-A78E-A1A9D8DBC4A9Q48830924-163C4ED8-BB58-4092-84B4-DB979C6AE649Q51615169-ADD8D55D-3B91-4A86-AB48-163B1DCB8CD0Q55515157-2F7B84A4-896C-4DA9-8DB7-D17EEB4F11F5Q58580354-F4BE6414-36D8-4D83-90D8-359242B6E768
P2860
Atorvastatin increases intestinal expression of NPC1L1 in hyperlipidemic men
description
2010 nî lūn-bûn
@nan
2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Atorvastatin increases intestinal expression of NPC1L1 in hyperlipidemic men
@ast
Atorvastatin increases intestinal expression of NPC1L1 in hyperlipidemic men
@en
Atorvastatin increases intestinal expression of NPC1L1 in hyperlipidemic men
@nl
type
label
Atorvastatin increases intestinal expression of NPC1L1 in hyperlipidemic men
@ast
Atorvastatin increases intestinal expression of NPC1L1 in hyperlipidemic men
@en
Atorvastatin increases intestinal expression of NPC1L1 in hyperlipidemic men
@nl
prefLabel
Atorvastatin increases intestinal expression of NPC1L1 in hyperlipidemic men
@ast
Atorvastatin increases intestinal expression of NPC1L1 in hyperlipidemic men
@en
Atorvastatin increases intestinal expression of NPC1L1 in hyperlipidemic men
@nl
P2093
P2860
P356
P1476
Atorvastatin increases intestinal expression of NPC1L1 in hyperlipidemic men
@en
P2093
André J Tremblay
Benoît Lamarche
Harry R Davis
Lizbeth Hoos
Patrick Couture
Suzanne Benjannet
Valéry Lemelin
P2860
P304
P356
10.1194/JLR.M011080
P577
2010-12-01T00:00:00Z